Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

The U.S. mRNA therapeutics CDMO market is driven by biotech demand for mRNA in vaccines and cancer treatments, using CDMO ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Federal funding cuts to vaccine research have impacted scientists nationwide — and some of those cuts hit close to home.

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

RNA vaccine technology has emerged as a groundbreaking approach in the field of immunology and infectious disease prevention.

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in ...

CHARLESTON, S.C. (WCSC) - The Trump administration started to cut funding from messenger ribonucleic acid vaccine research earlier this month, impacting more than 20 contracts for vaccine development.

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...